Adverse event development in clinical oncology trials – Authors' reply

Gita Thanarajasingam; Jeff A. Sloan; Axel Grothey

doi:10.1016/S1470-2045(16)30245-5

Adverse event development in clinical oncology trials – Authors' reply

Gita Thanarajasingam, Jeff A. Sloan, Axel Grothey

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e264-e265
Journal	The Lancet Oncology
Volume	17
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(16)30245-5
State	Published - Jul 1 2016

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(16)30245-5

Cite this

@article{e3bc4bf9a8524fcaafb7bcd8d140032b,

title = "Adverse event development in clinical oncology trials – Authors' reply",

author = "Gita Thanarajasingam and Sloan, {Jeff A.} and Axel Grothey",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/S1470-2045(16)30245-5",

language = "English (US)",

volume = "17",

pages = "e264--e265",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

TY - JOUR

T1 - Adverse event development in clinical oncology trials – Authors' reply

AU - Thanarajasingam, Gita

AU - Sloan, Jeff A.

AU - Grothey, Axel

PY - 2016/7/1

Y1 - 2016/7/1

UR - http://www.scopus.com/inward/record.url?scp=84991073154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991073154&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30245-5

DO - 10.1016/S1470-2045(16)30245-5

M3 - Letter

C2 - 27396640

AN - SCOPUS:84991073154

SN - 1470-2045

VL - 17

SP - e264-e265

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 7

ER -

Adverse event development in clinical oncology trials – Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this